Literature DB >> 25228003

Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale.

Gabriella Santangelo1, Paolo Barone, Sofia Cuoco, Simona Raimo, Domenica Pezzella, Marina Picillo, Roberto Erro, Marcello Moccia, Maria Teresa Pellecchia, Marianna Amboni, Franco Santangelo, Santangelo Franco, Dario Grossi, Luigi Trojano, Carmine Vitale.   

Abstract

Apathy is a behavioural disturbance occurring alone or in concomitance with depression in Parkinson's disease (PD). Here we present a validation study for the self-report version of the Apathy Evaluation Scale (AES-S), carried out in a sample of 60 non-demented, non-depressed untreated, drug-naïve, de novo PD patients; 20 patients of the sample (33.3%) were classified as apathetic according to current clinical criteria. All enrolled patients completed the AES-S and a neurological and cognitive assessment. Mean AES-S score was 34.43. AES-S did not show floor or ceiling effect. Cronbach's alpha was 0.872. Principal component analysis revealed three factors: the first (34.4% of the variance) represented constitutive aspects of the construct of apathy; the second (8.5% of the variance) represented a social dimension; the third factor (7.9% of the variance) represented a dimension related to insight. With respect to clinical criteria for apathy considered as the gold standard, receiver operating characteristics curve analysis showed that a cut-off of 36/37 has the maximum discrimination power. High sensitivity and negative predictive values were obtained with cut-off scores of 33/34 or lower; high specificity and positive predictive values were obtained with cut-off scores of 38/39 or higher. AES-S score correlated with scores on frontal tasks, but not on Beck Depression Inventory, Unified Parkinson's Disease Rating Scale, Hoehn and Yahr scale. The AES-S is a reliable and valid questionnaire for detecting apathy in PD. For screening purposes a 33/34 cut-off score is indicated, but a 38/39 cut-off score is necessary when a high specificity is desired.

Entities:  

Mesh:

Year:  2014        PMID: 25228003     DOI: 10.1007/s00415-014-7498-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  49 in total

1.  Apathy in Parkinson's disease.

Authors:  G C Pluck; R G Brown
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-12       Impact factor: 10.154

2.  A normative study on visual reaction times and two Stroop colour-word tests.

Authors:  R Barbarotto; M Laiacona; R Frosio; M Vecchio; A Farinato; E Capitani
Journal:  Ital J Neurol Sci       Date:  1998-06

3.  The Frontal Assessment Battery (FAB): normative values in an Italian population sample.

Authors:  I Appollonio; M Leone; V Isella; F Piamarta; T Consoli; M L Villa; E Forapani; A Russo; P Nichelli
Journal:  Neurol Sci       Date:  2005-06       Impact factor: 3.307

Review 4.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

7.  Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease.

Authors:  Valeria Isella; Paola Melzi; Marco Grimaldi; Simona Iurlaro; Roberto Piolti; Carlo Ferrarese; Lodovico Frattola; Ildebrando Appollonio
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

Review 8.  Apathy: a neuropsychiatric syndrome.

Authors:  R S Marin
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

9.  Relationship between self-reported apathy and executive dysfunction in nondemented patients with Parkinson disease.

Authors:  Dennis J Zgaljardic; Joan C Borod; Nancy S Foldi; Mary Rocco; Paul J Mattis; Mark F Gordon; Andrew S Feigin; David Eidelberg
Journal:  Cogn Behav Neurol       Date:  2007-09       Impact factor: 1.600

Review 10.  Apathy in Parkinson's disease: diagnosis, neuropsychological correlates, pathophysiology and treatment.

Authors:  Gabriella Santangelo; Luigi Trojano; Paolo Barone; Domenico Errico; Dario Grossi; Carmine Vitale
Journal:  Behav Neurol       Date:  2013-01-01       Impact factor: 3.342

View more
  29 in total

1.  Italian version of the Starkstein Apathy Scale (SAS-I) and a shortened version (SAS-6) to assess "pure apathy" symptoms: normative study on 392 individuals.

Authors:  Elisabetta Garofalo; Alessandro Iavarone; Sergio Chieffi; Michele Carpinelli Mazzi; Nadia Gamboz; Ferdinando Ivano Ambra; Maria Sannino; Filomena Galeone; Sabrina Esposito; Bruno Ronga; Ciro Rosario Ilardi
Journal:  Neurol Sci       Date:  2020-07-29       Impact factor: 3.307

Review 2.  Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders.

Authors:  Luigi Trojano; Costanza Papagno
Journal:  Neurol Sci       Date:  2017-10-16       Impact factor: 3.307

3.  Assessment of apathy independent of physical disability: validation of the Dimensional Apathy Scale in Italian healthy sample.

Authors:  Gabriella Santangelo; Simona Raimo; Mattia Siciliano; Alfonsina D'Iorio; Fausta Piscopo; Sofia Cuoco; Marianna Bottone; Francesca Trojsi; Dario Grossi; Luigi Trojano
Journal:  Neurol Sci       Date:  2016-11-14       Impact factor: 3.307

Review 4.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

5.  Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Authors:  Gabriella Santangelo; Sofia Cuoco; Maria Teresa Pellecchia; Roberto Erro; Paolo Barone; Marina Picillo
Journal:  J Neurol       Date:  2018-09-03       Impact factor: 4.849

6.  Assessment of apathy minimising the effect of motor dysfunctions in Parkinson's disease: a validation study of the dimensional apathy scale.

Authors:  Gabriella Santangelo; Alfonsina D'Iorio; Fausta Piscopo; Sofia Cuoco; Katia Longo; Marianna Amboni; Chiara Baiano; Domenico Tafuri; Maria Teresa Pellecchia; Paolo Barone; Carmine Vitale
Journal:  Qual Life Res       Date:  2017-04-07       Impact factor: 4.147

7.  Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease.

Authors:  Ulrike Lueken; Ricarda Evens; Monika Balzer-Geldsetzer; Simon Baudrexel; Richard Dodel; Susanne Gräber-Sultan; Rüdiger Hilker-Roggendorf; Elke Kalbe; Oliver Kaut; Brit Mollenhauer; Kathrin Reetz; Eva Schäffer; Nele Schmidt; Jörg B Schulz; Annika Spottke; Karsten Witt; Katharina Linse; Alexander Storch; Oliver Riedel
Journal:  Int J Methods Psychiatr Res       Date:  2017-04-18       Impact factor: 4.035

8.  Serum uric acid is associated with apathy in early, drug-naïve Parkinson's disease.

Authors:  Marina Picillo; Gabriella Santangelo; Marcello Moccia; Roberto Erro; Marianna Amboni; Elio Prestipino; Katia Longo; Carmine Vitale; Emanuele Spina; Giuseppe Orefice; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neural Transm (Vienna)       Date:  2016-01-06       Impact factor: 3.575

9.  Connected speech in progressive supranuclear palsy: a possible role in differential diagnosis.

Authors:  Eleonora Del Prete; Luca Tommasini; Sonia Mazzucchi; Daniela Frosini; Giovanni Palermo; Riccardo Morganti; Cristina Pagni; Gloria Tognoni; Ubaldo Bonuccelli; Roberto Ceravolo
Journal:  Neurol Sci       Date:  2020-08-27       Impact factor: 3.307

10.  Apathy in Parkinson's disease: differences between caregiver's report and self-evaluation.

Authors:  V Valentino; Alessandro Iavarone; M Amboni; F Moschiano; M Picillo; V Petretta; G Cicarelli
Journal:  Funct Neurol       Date:  2018 Jan/Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.